Screening and primary prevention of colorectal cancer: A review of sex-specific and site-specific differences

Journal of Medical Screening

Volumn 20, Issue 3, 2013, Pages 125-148

  Massat, Nathalie J ^a   Moss, Sue M ^a   Halloran, Stephen P ^b   Duffy, Stephen W ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Colorectal cancer; Faecal occult blood test; Flexible sigmoidoscopy; Guaiac; Immunochemical; Screening; Sex specific; Site specific

Indexed keywords

ACETYLSALICYLIC ACID; GUAIAC;

AGED; COLORECTAL CANCER; COLORECTAL TUMOR; FAECAL OCCULT BLOOD TEST; FEMALE; FLEXIBLE SIGMOIDOSCOPY; HUMAN; IMMUNOCHEMICAL; INCIDENCE; MALE; MASS SCREENING; META ANALYSIS; MIDDLE AGED; OCCULT BLOOD; PATHOLOGY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SEX RATIO; SEX-SPECIFIC; SIGMOIDOSCOPY; SITE-SPECIFIC; UNITED KINGDOM;

ASPIRIN; COLORECTAL CANCER; FAECAL OCCULT BLOOD TEST; FLEXIBLE SIGMOIDOSCOPY; GUAIAC; IMMUNOCHEMICAL; SCREENING; SEX-SPECIFIC; SITE-SPECIFIC;

AGED; ASPIRIN; COLORECTAL NEOPLASMS; ENGLAND; FEMALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX DISTRIBUTION; SIGMOIDOSCOPY;

EID: 84901372841     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141313501292     Document Type: Review

References (107)

1. Cancer Research UK, Bowel Cancer Statistics [http:// www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/]
2. Nguyen SP, Bent S, Chen YH, et al. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7(6): 676-681.
3. Ferlitsch MRKPS, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA: The Journal of the American Medical Association 2011;306(12): 1352-1358.
4. Koo JH, Leong RWL. Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. Journal of Gastroenterology and Hepatology 2010;25(1): 33-42.
5. Jones AM, Morris E, Thomas J, et al. Evaluation of bowel cancer registration data in England, 1996-2004. Br J Cancer 2009;101(8): 1269-1273.
6. Curado M, Edwards B, Shin H, et al. Cancer Incidence in Five Continents. IARC Scientific Publications 2007;IX(160): 466-481.
7. Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Digestive diseases 1997;15(4-5): 302-311.
8. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. British Journal of Surgery 2002;89(7): 845-860.
9. Littlejohn C, Hilton S, Macfarlane GJ, et al. Systematic review and meta-analysis of the evidence for flexible sig-moidoscopy as a screening method for the prevention of colorectal cancer. British Journal of Surgery 2012;99(11): 1488-1500.
10. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): An update. American Journal of Gastroenterology 2008;103(6): 1541-1549.
11. Hewitson P, Glasziou P, Irwig L, et al. Screening for colo-rectal cancer using the faecal occult blood test, Hemoccult. Cochrane database of systematic reviews (Online) 2007;Jan 24(1): CD001216.
12. Mandel JS, Church TR, Bond JH, et al. The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer. New England Journal of Medicine 2000;343(22): 1603-1607.
13. Steele RJ, Kostourou I, McClements P, et al. Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen 2010;17(2): 68-74.
14. Logan RF, Patnick J, Nickerson C, et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012;61(10): 1439-1446.
15. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, et al. A novel hypothesis on the sensitivity of the fecal occult blood test. Cancer 2009;115(11): 2410-2419.
16. Halloran SP, Launoy G, Zappa M International Agency for Research on C. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition- Faecal occult blood testing. Endoscopy 2012;44(Suppl 3): SE65-87.
17. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immu-nochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26(3): 131-147.
18. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135(1): 82-90.
19. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010a;59(01): 62-68.
20. Allison JE, Sakoda LC, Levin TR, et al. Screening for color-ectal neoplasms with new fecal occult blood tests: update on performance characteristics. Journal of the National Cancer Institute 2007;99(19): 1462-1470.
21. Park DI, Ryu S, Kim Y-H, et al. Comparison of Guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105(9): 2017-2025.
22. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454(7203): 436-444.
23. Greenhough A, Smartt HJM, Moore AE, et al. The COX-2/ PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30(3): 377-386.
24. Hyde CAC, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. International Immunopharmacology 2009;9(6): 701-715.
25. Bretthauer M. Colorectal cancer screening. J Intern Med 2011;270(2): 87-98.
26. Rabeneck L, Zwaal C, Goodman JH, et al. Cancer Care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: evidentiary base and recommendations. Clinical Biochemistry 2008;41(16-17): 1289-1305.
27. Basu A, Smartt P. Comparison of diagnostic accuracy between immunochemical and guaiac based faecal occult blood tests for colorectal cancer detection. HSAC Report 2009;2(5).
28. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Practice & Research Clinical Gastroenterology 2010;24(4): 479-492.
29. Zhu MM, Xu XT, Nie F, et al. Comparison of immuno-chemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta-analysis. Journal of Digestive Diseases 2010;11(3): 148-160.
30. van Roon A, van Dam L, Zauber A, et al. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals (Protocol). The Cochrane Collaboration 2011, http://sum-maries.cochrane.org/CD009276/
31. Egger M, Davey Smith G, Altman D. Systematic reviews in health care: meta-analysis in context. BMJ Books 2001, 2nd ed.
32. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Statistics in Medicine 1997;16(9): 1017-1029.
33. Stryhn H, Christensen J. Confidence intervals by the profile likelihood method, with applications in veterinary epidemiology [Abstract]. International Symposia on Veterinary Epidemiology and Economics (ISVEE), Vina del Mar, Chile 2003.
34. Cheng H, Macaluso M. Comparison of the accuracy of two tests with a confirmatory procedure limited to positive results. Epidemiology 1997;8(1): 104-106.
35. Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Statistics in Medicine 2001;20(6): 935-949.
36. Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006;107(9): 2152-2159.
37. Cheng TI, Wong JM, Hong CF, et al. Colorectal cancer screening in asymptomatic adults: Comparison of colonos-copy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002;101(10): 685-690.
38. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58(2): 241-248.
39. Thiis-Evensen E, Hoff GS, Sauar J, et al. Population-based surveillance by colonoscopy: effect on the incidence of color-ectal cancer: telemark polyp study I. Scandinavian Journal of Gastroenterology 1999;34(4): 414-420.
40. Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846.
41. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. The Lancet 2010;375(9726): 1624-1633.
42. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoid-oscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011;103(17): 1310-1322.
43. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sig-moidoscopy. The New England journal of medicine 2012;366(25): 2345-2357.
44. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149(9): 638-658.
45. Hewitson P. Review: faecal occult blood test screening reduces risk of colorectal cancer mortality. Evidence Based Medicine 2009;14(1). DOI: 10.1002/14651858.
46. Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61(7): 1036-1040.
47. Kronborg O, Jorgensen OD, Fenger C, et al. Randomized study of biennial screening with a faecal occult blood test: Results after nine screening rounds. Scandinavian Journal of Gastroenterology 2004;39(9): 846-851.
48. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. British Journal of Surgery 2008;95(8): 1029-1036.
49. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150(3): 162-169.
50. Wong CK, Fedorak RN, Prosser CI, et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 2012;27(12): 1657-1664.
51. Parker MA, Robinson MHE, Scholefield JH, et al. Psychiatric morbidity and screening for colorectal cancer. Journal of Medical Screening 2002;9(1): 7-10.
52. Petrelli N, Michalek AM, Freedman A, et al. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surgical Oncology 1994;3(1): 27-36.
53. Robinson MHE, Marks CG, Farrands PA, et al. Population screening for colorectal cancer: Comparison between guaiac and immunological faecal occult blood tests. British Journal of Surgery 1994;81(3): 448-451.
54. Allison JE, Tekawa IS, Ransom LJ, et al. A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening. New England Journal of Medicine 1996;334(3): 155-160.
55. Castiglione G, Zappa M, Grazzini G, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996;74(1): 141-144.
56. Hoepffner N, Shastri YM, Hanisch E, et al. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther 2006;23(1): 145-154.
57. Dancourt V, Lejeune C, Lepage C, et al. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. European Journal of Cancer 2008;44(15): 2254-2258.
58. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56(2): 210-214.
59. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009;100(8): 1230-1235.
60. Parra-Blanco A, Gimeno-Garcia A, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. Journal of Gastroenterology 2010;45(7): 703-712.
61. Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. European Journal of Cancer 2012;48(16): 2969-2976.
62. Brenner H, Haug U, Hundt S. Sex Differences in Performance of Fecal Occult Blood Testing. Am J Gastroenterol 2010a;105(11): 2457-2464.
63. Garcia M, Mila N, Binefa G, et al. False-positive results from colorectal cancer screening in Catalonia (Spain), 2000-2010. J Med Screen 2012;19(2): 77-82.
64. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. The Lancet 2007;369(9573): 1603-1613.
65. Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet 2010;376(9754): 1741-1750.
66. Gann PH, Manson JE, Glynn RJ, et al. Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized Trial. Journal of the National Cancer Institute 1993;85(15): 1220-1224.
67. Sturmer T, Glynn RJ, Lee I-M, et al. Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study. Annals of Internal Medicine 1998;128(9): 713-720.
68. Cook NR, Lee I-M, Gaziano JM, et al. Low-Dose Aspirin in the Primary Prevention of Cancer. JAMA: The Journal of the American Medical Association 2005;294(1): 47-55.
69. Cook NR: Aspirin and cancer: Evidence from randomized trials. 8th NCRI Cancer Conference 4-7 November 2012 2012, Parallel sessions Abstract 89.
70. Wardle J, Miles A, Atkin W. Gender differences in utilization of colorectal cancer screening. Journal of Medical Screening 2005;12(1): 20-27.
71. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible Sigmoidoscopy in the PLCO Cancer Screening Trial: Results From the Baseline Screening Examination of a Randomized Trial. Journal of the National Cancer Institute 2005;97(13): 989-997.
72. Lo S, Vart G, Snowball J, et al. The impact of media coverage of the Flexible Sigmoidoscopy Trial on English colorec-tal screening uptake. Journal of Medical Screening 2012;19(2): 83-88.
73. Ventura L, Mantellini P, Grazzini G: The effect of introduction of immunochemical faecal occult blood testing on colo-rectal cancer incidence. International Cancer Screening Network Biennial Meeting, Sydney Australia October 23-25 2012 2012, Poster 51.
74. Brevinge H, Lindholm E, Buntzen S, et al. Screening for colo-rectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55 - 56 years' old population. Int J Colorect Dis 1997;12(5): 291-295.
75. Berry DP, Clarke P, Hardcastle JD, et al. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. British Journal of Surgery 1997;84(9): 1274-1276.
76. Rasmussen M, Kronborg O, Fenger C, et al. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol 1999;34(1): 73-78.
77. Hol L, de Jonge V, van Leerdam ME, et al. Screening for colorectal cancer: Comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochem-ical test and flexible sigmoidoscopy. European Journal of Cancer 2010b;46(11): 2059-2066.
78. Segnan N, Senore C, Andreoni B, et al. Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. Journal of the National Cancer Institute 2005;97(5): 347-357.
79. Segnan N, Senore C, Andreoni B, et al. Comparing Attendance and Detection Rate of Colonoscopy With Sigmoidoscopy and FIT for Colorectal Cancer Screening. Gastroenterology 2007;132(7): 2304-2312.
80. Moss SM, Campbell C, Melia J, et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut 2012;61(1): 101-107.
81. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening - an overview. Best Pract Res Clin Gastroenterol 2010;24(4): 439-449.
82. Whyte S, Chilcott J, Halloran S. Reappraisal of the options for colorectal cancer screening in England. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 2012;14(9): e547-561.
83. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. International Journal of Cancer 2011;128(10): 2415-2424.
84. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: A systematic review and meta-analysis. Preventive Medicine 2012;55(2): 87-92.
85. Deutekom M, van Rossum LGM, van Rijn AF, et al. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: The patient perspective. Scandinavian Journal of Gastroenterology 2010;45(11): 1345-1349.
86. Schottinger J, Kanter M, Palmer-Toy D. Reducing the risk of overpapulation: Achieving more by doing less. International Cancer Screening Network Biennial Meeting, Sydney Australia October 23-25 2012 2012, Poster 47.
87. Birkenfeld S, Belfer RG, Chared M, et al. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test. Journal of Medical Screening 2011;18(3): 135-141.
88. Chubak J, Bogart A, Laing S, Green B: Comparing uptake of fecal occult blood tests for colorectal cancer screening: Results from a randomized controlled trial. International Cancer Screening Network Biennial Meeting, Sydney Australia October 23-25 2012 2012, Poster 28.
89. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012;23(7): 526-536.
90. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet 2011;377(9759): 31-41.
91. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet 2012a;379(9826): 1602-1612.
92. Jacobs EJ, Newton CC, Gapstur SM, et al. Daily Aspirin Use and Cancer Mortality in a Large US Cohort. Journal of the National Cancer Institute 2012;104(16): 1208-1217.
93. Siller-Matula JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? JAMA: The Journal of the American Medical Association 2012;307(21): 2318-2320.
94. Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol 2012;27(5): 499-507.
95. De Berardis GLGDEA, et al. ASsociation of aspirin use with major bleeding in patients with and without diabetes. JAMA: The Journal of the American Medical Association 2012;307(21): 2286-2294.
96. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 2009;373(9678): 1849-1860.
97. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet 2012b;379(9826): 1591-1601.
98. Sharma JN, Jawad NM. Adverse Effects of COX-2 Inhibitors. TheScientificWorldJOURNAL 2005;5:629-645.
99. Kawada N, Moriyama T, Kitamura H, et al. Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs. Clin Exp Nephrol 2012;16(1): 25-29.
100. Lanas A, McCarthy D, Voelker M, et al. Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds - Gastrointestinal Adverse Effects: A Meta-Analysis of Randomized Clinical Trials. Drugs in R&D 2011b;11(3): 277-288.
101. Peterson J, Zurakowski D, Italiano J Jr, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012;15(2): 265-273.
102. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11(2): 123-134.
103. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thrombosis and Haemostasis 2008;99(1): 14-26.
104. Siller-Matula JM, Delle-Karth G, Christ G, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. International Journal of Cardiology 2013;167(2): 430-435.
105. Frelinger AL, Li Y, Linden MD, et al. Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization. Circulation 2009;120(25): 2586-2596.
106. McClements PL, Madurasinghe V, Thomson CS, et al. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiology 2012;36(4): e232-e242.
107. Brenner H, Hoffmeister M, Arndt V, et al. Gender differences in colorectal cancer: implications for age at initiation of screening. Br J Cancer 2007;96(5): 828-831.